<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00076401</url>
  </required_header>
  <id_info>
    <org_study_id>PCYC-0216</org_study_id>
    <nct_id>NCT00076401</nct_id>
  </id_info>
  <brief_title>A Study of Motexafin Gadolinium for the Treatment of Chronic Lymphocytic Leukemia (CLL)</brief_title>
  <official_title>Phase II Trial of Motexafin Gadolinium (MGd) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharmacyclics LLC.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pharmacyclics LLC.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if the drug motexafin gadolinium will be an
      effective treatment for patients who have chronic lymphocytic leukemia (CLL) that has come
      back after treatment or that has stopped responding to treatment.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>27</enrollment>
  <condition>Leukemia</condition>
  <condition>Leukemia, Lymphocytic, Chronic</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Motexafin gadolinium</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 18 years old

          -  Refractory or relapsed CLL

          -  ECOG performance status score of 0, 1, or 2

          -  Each patient must sign a study-specific informed consent form

        Exclusion Criteria:

        Laboratory values of:

          -  Platelet count &lt;30,000/uL

          -  AST or ALT &gt;2 x the upper limit of normal (ULN)

          -  Total bilirubin &gt;2 x ULN

          -  Creatinine &gt;2.0 mg/dL

          -  Chemotherapy, radiation therapy, immunotherapy, systemic corticosteroids, or systemic
             biologic anticancer therapy within 21 days before beginning study treatment

          -  Women who are pregnant or lactating
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 21, 2004</study_first_submitted>
  <study_first_submitted_qc>January 23, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2004</study_first_posted>
  <last_update_submitted>June 25, 2014</last_update_submitted>
  <last_update_submitted_qc>June 25, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CLL</keyword>
  <keyword>chronic lymphocytic leukemia</keyword>
  <keyword>relapsed chronic lymphocytic leukemia</keyword>
  <keyword>refractory chronic lymphocytic leukemia</keyword>
  <keyword>Leukemia</keyword>
  <keyword>Motexafin gadolinium</keyword>
  <keyword>Chronic leukemia</keyword>
  <keyword>Lymphocytic leukemia, chronic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motexafin gadolinium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

